Recent Updates
Recently added Catalysts

MK0859

Phase 1

Hypercholesterolemia | Small molecule | Metabolic |Merck & Company, Inc.|Last Updated: Feb 25, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment50
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00565292A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)PHASE1 COMPLETED 50Jul 1, 2006Aug 1, 2006Feb 25, 2015 -
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0859DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Patient is between 18 and 75 years of age * Patient can be on a stable diet for the study * Patient has a stable weight for more then 6 weeks before the study and has not participated in a weight loss program Exclusion Criteria: * Patient has chronic heart failure or a histo...

Unlock Eligibility Criteria